MiNK Therapeutics (INKT) Short Interest Ratio & Short Volume $0.52 +0.02 (+4.76%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends MiNK Therapeutics Short Interest DataMiNK Therapeutics (INKT) has a short interest of 43,000 shares, representing 0.43% of the float (the number of shares available for trading by the public). This marks a -15.19% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.1, indicating that it would take 1.1 days of the average trading volume of 85,920 shares to cover all short positions.Current Short Interest43,000 sharesPrevious Short Interest50,700 sharesChange Vs. Previous Month-15.19%Dollar Volume Sold Short$31,519.00Short Interest Ratio1.1 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares39,550,000 sharesFloat Size9,930,000 sharesShort Percent of Float0.43%Today's Trading Volume101,490 sharesAverage Trading Volume85,920 sharesToday's Volume Vs. Average118% Short Selling MiNK Therapeutics? Sign up to receive the latest short interest report for MiNK Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartINKT Short Interest Over TimeINKT Days to Cover Over TimeINKT Percentage of Float Shorted Over Time Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol MiNK Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/202443,000 shares $31,519.00 -15.2%0.4%1.1 $0.73 11/15/202450,700 shares $38,227.80 -1.9%0.5%1.4 $0.75 10/31/202451,700 shares $36,913.80 -20.8%0.5%1.5 $0.71 10/15/202465,300 shares $43,424.50 +34.4%0.7%1.7 $0.67 9/30/202448,600 shares $36,450.00 -21.6%0.5%0.8 $0.75 9/15/202462,000 shares $48,081.00 +22.5%0.6%1.2 $0.78 Get the Latest News and Ratings for INKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/202450,600 shares $40,986.00 -21.3%0.5%0.9 $0.81 8/15/202464,300 shares $52,790.30 +5.1%1.1%1 $0.82 7/31/202461,200 shares $57,528.00 -27.9%1.2%0.4 $0.94 7/15/202484,900 shares $96,786.00 -10.3%1.6%0.6 $1.14 6/30/202494,600 shares $89,794.32 -19.6%1.8%0.6 $0.95 6/15/2024117,600 shares $108,156.72 -31.4%2.2%0.6 $0.92 5/31/2024171,300 shares $166,161.00 -66.9%3.2%0.9 $0.97 5/15/2024516,900 shares $537,576.00 +490.7%5.2%2.8 $1.04 4/30/202487,500 shares $86,625.00 +80.4%0.9%0.9 $0.99 4/15/202448,500 shares $44,062.25 +18.0%0.5%0.5 $0.91 3/31/202441,100 shares $37,331.13 -11.6%0.4%0.4 $0.91 3/15/202446,500 shares $41,594.25 +12.6%0.5%0.8 $0.89 2/29/202441,300 shares $38,049.69 -76.4%0.4%0.7 $0.92 2/15/2024175,100 shares $162,843.00 -7.6%1.8%3.4 $0.93 1/31/2024189,400 shares $163,831.00 +8.3%2.0%3.8 $0.87 1/15/2024174,900 shares $172,976.10 -1.7%1.8%3.8 $0.99 12/31/2023178,000 shares $190,460.00 +237.8%1.9%4.6 $1.07 12/15/202352,700 shares $53,754.00 -66.3%0.6%1.2 $1.02 11/30/2023156,400 shares $164,220.00 +2.4%1.6%3.9 $1.05 11/15/2023152,700 shares $155,754.00 -19.7%1.6%3.4 $1.02 10/31/2023190,100 shares $193,902.00 +11.7%2.0%3.6 $1.02 10/15/2023170,200 shares $187,220.00 +6.7%1.8%3 $1.10 9/30/2023159,500 shares $175,450.00 -11.7%1.8%2.4 $1.10 9/15/2023180,600 shares $232,974.00 -7.7%1.9%2.5 $1.29 8/31/2023195,700 shares $283,765.00 -1.0%2.1%1.9 $1.45 8/15/2023197,600 shares $337,896.00 -31.4%2.0%1.8 $1.71 7/31/2023288,000 shares $538,560.00 +6.9%3.0%2.1 $1.87 7/15/2023269,500 shares $493,185.00 +1.7%2.8%1.4 $1.83 6/30/2023264,900 shares $556,290.00 +68.5%2.7%1.4 $2.10 6/15/2023157,200 shares $377,280.00 +2.0%1.6%0.9 $2.40 5/31/2023154,100 shares $271,216.00 -14.6%1.7%1.2 $1.76 5/15/2023180,500 shares $305,045.00 +70.4%1.9%1.5 $1.69 4/30/2023105,900 shares $189,561.00 +117.5%1.1%1.1 $1.79 4/15/202348,700 shares $107,627.00 +34.2%1.1%2.8 $2.21Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. 3/31/202336,300 shares $68,788.50 -14.0%0.8%3.2 $1.90 3/15/202342,200 shares $84,822.00 +92.7%1.0%3.6 $2.01 2/28/202321,900 shares $44,457.00 -60.9%0.5%2.2 $2.03 2/15/202356,000 shares $112,560.00 -19.4%1.3%4.6 $2.01 1/31/202369,500 shares $159,155.00 -10.6%1.6%3.2 $2.29 1/15/202377,700 shares $183,372.00 -15.2%1.7%3.4 $2.36 12/30/202291,600 shares $239,076.00 -7.0%2.0%3.9 $2.61 12/15/202298,500 shares $217,685.00 -34.9%2.1%4 $2.21 11/30/2022151,400 shares $401,210.00 -7.4%3.3%5.2 $2.65 11/15/2022163,500 shares $501,667.05 +24.0%3.5%4.6 $3.07 10/31/2022131,900 shares $287,542.00 +3.2%2.8%0.3 $2.18 10/15/2022127,800 shares $241,542.00 -0.8%2.8%0.3 $1.89 9/30/2022128,800 shares $271,768.00 +25.1%2.8%0.3 $2.11 9/15/2022103,000 shares $269,860.00 -46.1%2.2%0.2 $2.62 8/31/2022191,200 shares $502,856.00 +15.3%4.2%0.4 $2.63 8/15/2022165,800 shares $563,720.00 +400.9%3.7%0.4 $3.40 7/31/202233,100 shares $43,361.00 +0.3%0.8%0.8 $1.31 7/15/202233,000 shares $42,570.00 -35.6%0.8%0.8 $1.29 6/30/202251,200 shares $72,192.00 -57.2%1.2%0.9 $1.41 6/15/2022119,500 shares $223,465.00 -1.6%2.9%2 $1.87 5/31/2022121,400 shares $188,170.00 +33.6%2.9%2 $1.55 5/15/202290,900 shares $117,261.00 -16.0%2.2%1.4 $1.29 4/30/2022108,200 shares $242,368.00 -32.5%2.6%1.7 $2.24 4/15/2022160,400 shares $469,972.00 +5.0%3.8%2.2 $2.93 3/31/2022152,800 shares $343,800.00 -2.4%3.7%2 $2.25 3/15/2022156,500 shares $355,255.00 -7.6%3.8%1.9 $2.27 2/28/2022169,400 shares $503,118.00 +5.2%4.2%1.9 $2.97 2/15/2022161,000 shares $457,240.00 -21.8%4.0%1.7 $2.84 1/31/2022205,800 shares $677,082.00 -11.3%5.1%2.2 $3.29 1/15/2022231,900 shares $735,123.00 +139.1%N/A2.2 $3.17 12/31/202197,000 shares $432,620.00 No Change2.4%0.9 $4.46 INKT Short Interest - Frequently Asked Questions What is MiNK Therapeutics' current short interest? Short interest is the volume of MiNK Therapeutics shares that have been sold short but have not yet been covered or closed out. As of November 30th, investors have sold 43,000 shares of INKT short. 0.43% of MiNK Therapeutics' shares are currently sold short. Learn More on MiNK Therapeutics' current short interest. What is a good short interest ratio for MiNK Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. INKT shares currently have a short interest ratio of 1.0. Learn More on MiNK Therapeutics's short interest ratio. What is a good short interest percentage for MiNK Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.43% of MiNK Therapeutics' floating shares are currently sold short. Is MiNK Therapeutics' short interest increasing or decreasing? MiNK Therapeutics saw a decrease in short interest in the month of November. As of November 30th, there was short interest totaling 43,000 shares, a decrease of 15.2% from the previous total of 50,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is MiNK Therapeutics' float size? MiNK Therapeutics currently has issued a total of 39,550,000 shares. Some of MiNK Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. MiNK Therapeutics currently has a public float of 9,930,000 shares. How does MiNK Therapeutics' short interest compare to its competitors? 0.43% of MiNK Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to MiNK Therapeutics: Rani Therapeutics Holdings, Inc. (6.80%), Assertio Holdings, Inc. (5.80%), Anixa Biosciences, Inc. (1.21%), Adagene Inc. (0.09%), PowerUp Acquisition Corp. (0.06%), CytomX Therapeutics, Inc. (5.61%), 23andMe Holding Co. (5.93%), Adlai Nortye Ltd. (0.01%), Karyopharm Therapeutics Inc. (14.99%), Reviva Pharmaceuticals Holdings, Inc. (18.42%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short MiNK Therapeutics stock? Short selling INKT is an investing strategy that aims to generate trading profit from MiNK Therapeutics as its price is falling. INKT shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against MiNK Therapeutics? A short squeeze for MiNK Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of INKT, which in turn drives the price of the stock up even further. How often is MiNK Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INKT, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies RANI Short Interest ASRT Short Interest ANIX Short Interest ADAG Short Interest PWUP Short Interest CTMX Short Interest ME Short Interest ANL Short Interest KPTI Short Interest RVPH Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:INKT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INKT Stock Alerts